PT  - JOURNAL ARTICLE
AU  - Alhamlan, Fatimah S.
AU  - Alqahtani, Ahmed A.
AU  - Bakheet, Dana M.
AU  - Bohol, Marie F.
AU  - Althawadi, Sahar I.
AU  - Mutabagani, Maysoon S.
AU  - Almaghrabi, Reem S.
AU  - Obied, Dalia A.
TI  - Development and Validation of Two In-house, Low-Cost SARS-CoV-2 Detection Assays
AID  - 10.1101/2020.05.18.20105510
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.18.20105510
4099  - http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105510.short
4100  - http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105510.full
AB  - Background One major challenge for detecting the virus that causes COVID-19 is commercial SARS-CoV-2 testing kit or reagent availability. To allow every laboratory or hospital access to an in-house assay, we developed two low-cost SARS-CoV-2 detection assay protocols using in-house primers and reagents/equipment on hand in most biology or diagnostic laboratories: a SYBR Green–based RT-PCR and PCR assays. RNA extraction has also become a major bottleneck due to limited supplies and the required labor. Thus, we validated alternative RNA extraction protocols.Methods SARS-CoV-2 genome sequences deposited into the GISAID database were retrieved to design and synthesize in-house primers. Forty patient samples were collected by nasopharyngeal swab, coded, and used to develop and validate the assay protocols. Both assays used TRIzol and heat-processing techniques to extract RNA from patient samples and to inactivate the virus; thus, testing was conducted in a conventional biosafety level 2 laboratory.Results The sensitivity and specificity of the primers were evaluated using samples previously confirmed positive for SARS-CoV-2. The positive amplicons were sequenced to confirm the results. The assay protocols were developed, and the specificity of each PCR product was confirmed using melting curve analyses. The most accurate heat-processing technique for primers with short amplicon lengths was 95 °C for 15 mins. Of 40 samples, both the SYBR Green–based quantitative RT-PCR assay and the PCR assay detected SARS-CoV-2 target genes in 28 samples, with no false-positive or false-negative results. These findings were 100% concordant with those of the diagnostic laboratory that tested the same samples using a Rotor-Gene PCR cycler with an Altona Diagnostics SARS-CoV-2 kit (R2=0.889).Conclusions These approaches are reliable, repeatable, specific, sensitive, simple, and low-cost tools for the detection of SARS-CoV-2 in a conventional biosafety level 2 laboratory, offering alternative approaches when commercial kits are unavailable or cost ineffective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the King Faisal Specialist Hospital and Research Centre COVID19 grant fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny needed data will be available upon request